Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Research Points to Potential Gene Therapy Improvements
Three Ways Research Could Improve Pancreatic Cancer Treatment
Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally
FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science
Pan-Mass Challenge Raises Record $78 Million for Dana-Farber Cancer Institute
CD123 Targeted Therapies
Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3
Menin Inhibitors: A New Class of Anti-Leukemic Agents
A Brighter Future for B-ALL in Adults
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Study Reveals Hidden Immune Defense Mechanism That Could Be Used to Fight Cancer
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Showing 91 - 105 of 1061 results
Previous| 1... 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 ...71 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
